PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

Lei Lei Wu

News Reporter

In 2015, Lieping Chen — the I/O researcher whose early work established the PD-1/PD-L1 as a cancer target and the co-founder of Amplimmune, bought out by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Merck is ‘well-positioned’ on Keytruda ahead of threatened pharma tariffs, CEO says

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

PD-L1 pi­o­neer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tu­mors

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors